James Gentrup, Senior Equity Analyst at micro-cap research firm Discovery Investment Research tells Proactive he thinks Canada-based Medexus Pharmaceuticals Inc (TSXV:MDP) (OTCQB:PDDPF) has a "solid" business with the company's single-dose auto-injector of methotrexate for the treatment of rheumatoid arthritis, and rates the company as a Speculative Buy with a price target of $7.65.
Gentrup says Medexus is one of only two major players who can deliver methotrexate to rheumatoid arthritis patients through its auto-injector method, and is impressed by the company's sales strategy to penetrate the US and Canadian markets.
